Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.

ConditionVitiligo

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorTanta University

About this trial

The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are:

Can the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used?

Participants will:

Visit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week.

Record any side effect they have during or after the sessions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients suffer from non-segmental stable vitiligo.

Patients who will accept to be included in the study and will sign a written consent.

Disqualifiers

Patients with history of koebnerization or any sign of disease activity.

Patients with keloid tendency.

Patients with active infection.

Pregnant or lactating woman.

Trial design

Design model

Single group

Treatments tested in this trial

microneedling with topical crisaborole
Procedure/Surgery
From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: the main patch with microneedling and topical crisaborole and two patches as controlOther 1 intervention

Trial outcomes

Primary outcomes

Repigmentation of vitiligo lesions

The repigmentation responses will be expressed qualitatively as the following No change (0%-25%) = mild improvement (26%-50%) = moderate improvement (51%-75%) = good improvement (76%-100%) = excellent improvement

Time frame

3 months from the start of treatment

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tanta University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: